Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726810 | 0.87 | APLNR (0.36) | APLNR | |
| SCHEMBL24925879 | 0.87 | APLNR (0.36) | APLNR | |
| SCHEMBL17835279 | 0.83 | APLNR (0.36) | APLNRSCN9A | |
| SCHEMBL17490614 | 0.83 | APLNR (0.36) | APLNRSCN9A | |
| SCHEMBL17835280 | 0.83 | APLNR (0.36) | APLNRSCN9A | |
| SCHEMBL16911985 | 0.79 | ARG1 (0.33) | APLNRSCN9AARG1 | |
| SCHEMBL28077323 | 0.79 | APLNR (0.43) | APLNRSCN9AARG1 | |
| SCHEMBL12584762 | 0.77 | — | — | |
| SCHEMBL22144017 | 0.77 | APLNR (0.34) | CYP1A2APLNR | |
| SCHEMBL6944623 | 0.77 | CYP1A2 (0.37) | CYP1A2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323000-B2 | Indole derivatives and their use in neurodegenerative diseases | P2RX3, ADORA2A, P2RX7 | CYP1A2 1409/4885APLNR 961/4885SCN9A 1398/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | CYP1A2 4665/4885APLNR 3423/4885SCN9A 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.